Biomarkers of Gemtuzumab Ozogamicin Response for Acute Myeloid Leukemia Treatment

Gemtuzumab ozogamicin (GO, Mylotarg(®)) consists of a humanized CD33-targeted antibody-drug conjugated to a calicheamicin derivative. Growing evidence of GO efficacy in acute myeloid leukemia (AML), demonstrated by improved outcomes in CD33-positive AML patients across phase I to III clinical trials...

Descripción completa

Detalles Bibliográficos
Autores principales: Fenwarth, Laurène, Fournier, Elise, Cheok, Meyling, Boyer, Thomas, Gonzales, Fanny, Castaigne, Sylvie, Boissel, Nicolas, Lambert, Juliette, Dombret, Hervé, Preudhomme, Claude, Duployez, Nicolas
Formato: Online Artículo Texto
Lenguaje:English
Publicado: MDPI 2020
Materias:
Review
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7460695/
https://www.ncbi.nlm.nih.gov/pubmed/32781546
http://dx.doi.org/10.3390/ijms21165626

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7460695/
https://www.ncbi.nlm.nih.gov/pubmed/32781546
http://dx.doi.org/10.3390/ijms21165626

Ejemplares similares